July 2002

Frontlines Image: Erica Johnson Damage control Researchers have found that inosine, a naturally occurring nucleoside whose levels are elevated in the brain following trauma, can induce axonal reorganization following a stroke and improve the performance of several sensorimotor tasks (P. Chen et al., "Inosine induces axonal rewiring and improves behavioral outcome after stroke," Proceedings of the National Academy of Sciences, 99:9031-6, June 25, 2002). A stroke can cause massive damage to t

Open Access, High Ambitions By Richard Gallagher   Fueled by scientists' resentment at perceived exploitation by established publishers, and driven by new opportunities in information technology, open access publishing burst onto the scene in biomedicine about five years ago. Most readers of The Scientist will be aware of the principal, two-part, argument in its favor, namely that: Maximum dissemination of properly peer-reviewed research is good for authors, good for funders, and, mos

What will the US Senate actually do about therapeutic cloning--the procedure of using nuclear transfer to derive embryonic stem cells?

Pew on Pew Regarding the Opinion by Henry I. Miller and Gregory Conko on genetically engineered foods,1 their criticisms of our recent report on food allergenicity research and our other efforts to promote dialogue and consensus on agricultural biotechnology issues are off the mark. Miller and Conko argue that the report2 reflects an "antibiotechnology" bias because it fails to stress that conventionally processed novel foods can also pose food allergy risks. Actually, the report discusses

Worst-case scenarios don't come much uglier than the plume of an aerosolized biowarfare agent infiltrating a city. What happens then? Do alarms ring, evacuations and vaccinations begin? Or will anyone even know what the cloud contains? The answer could depend on efforts to improve molecular recognition systems that identify biowarfare agents in the air, water, or food. Problems of accuracy and efficiency that have dogged such technologies for decades are approaching resolution, but even then,

Like some coevolutionary SWAT team, John Thompson, Bradley Cunningham, and colleagues have headed out every spring and summer for the last decade to the wilds of western Idaho and bordering areas in Oregon and Washington to camp out and infiltrate the world of the prairie starflower, Lithophragma parviflorum, and a little gray moth known as Greya politella. Now, their published rare case study in coevolution describes how the two species have coevolved in a variety of habitats, from open grass

Image: Courtesy of National Sciences Foundation Arabidopsis Plant genomics researchers stand at a crossroads. Behind them are the completed genome sequences of rice1 and the model mustard plant Arabidopsis thaliana.2 Now, armed with insights gained from both plant and animal sequencing projects, plant biologists must decide how to proceed with future sequencing, proteomics, and functional genomics endeavors--and how to allot precious basic research dollars while, at the same time, keeping

Genentech, the South San Francisco, Calif., biotech powerhouse, suffered a legal setback in June when a court ordered the company to pay more than $500 million (US) in damages to the nonprofit City of Hope National Medical Center in Duarte, Calif. A Los Angeles County Superior Court jury ruled that Genentech breached a 1976 contract with the institution when the company failed to pay the cancer center royalties from numerous third-party licenses that the company fraudulently concealed. In 197

A new patent on disease treatments that operate through a key biological trigger, the NF-kB messenger protein, has lawyers, university researchers, and technology transfer officers bracing for an intellectual property crackdown that they fear could reach into academia. Issued June 25, 2002, to a dozen researchers including David Baltimore, who identified the NF-kB signaling pathway, the patent was granted to the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Rese

Image: Courtesy of Aclara Biosciences The eTag™ system from ACLARA BioSciences of Mountain View, Calif., enables the multiplexed, solution-phase analysis of proteins and nucleic acids. This technology employs the company's eTag reporters, which are low-molecular weight, fluorescent molecules that are readily separated and quantified by capillary electrophoresis (CE) in conjunction with fluorescence detection using standard capillary DNA sequencers. This method can be used for any applic

Protein transfection, also called transduction, is the delivery of a biologically active protein or peptide directly into living cells.1 Pro-Ject™, a cationic lipid-based reagent, from Rockford, Ill.-based Pierce Biotechnology accomplishes this noninvasively--first, by noncovalently complexing with a protein, then fusing with or being endocytosed by the cell membrane, and finally, delivering a functional protein into the cytoplasm. Pro-Ject is fast and simple to use, with an average kit

Rapidly evolving genomic technologies have spawned the Tm/Luminex Universal Array Platform, capable of reading 10,000 single nucleotide polymorphisms (SNPs) per hour. Distributed by Luminex of Austin, Texas, the system is the product of a partnership between Luminex and Tm Bioscience of Toronto. Luminex pioneered multiplexed, bead-based genotyping with LabMAP™ (now called xMAP™).1 Tm Biosciences recently developed the Universal Array, an arbitrary set of nucleotide sequences for an

Image: Anne MacNamara Sophisticated European and UK investors seek potentially profitable deals with US biotechnology startups, which opens opportunities for American scientists at a time of caution in US capital markets. Between January 2001 and the end of March 2002, venture capitalists (VCs) based outside the United States raised 36 new funds to invest wholly or significantly in the life sciences. In the aggregate, those new funds represent $12 billion (US) for the life sciences and other t

Image: Anne MacNamara Cherlynn Mathias agonized over whether to report her allegations of scientific misconduct to the government and sought help from her parish priest. She still recalls the image of the church's art deco rectory, where she told the priest what she had learned about the ethics of research during her year at the University of Oklahoma (OU) in Tulsa and about her fear of retribution should she report the wrongdoing. At the end of the day, the priest asked, "What's the worst th

Image: Erica P. Johnson The Midwest Bioethics Center in Kansas City, Mo., runs a modest operation, so its officials rejoiced when they received $600,000 (US) from Bridgewater, NJ-based Aventis Pharmaceuticals. The grant will almost entirely fund a study on research integrity, and the center will host a conference on integrity in biomedical research in 2003 to culminate the work. "It's the best example of altruism," says Myra Christopher, president and CEO of MBC, which receives just $2 million

File Photo Brittney-Shea Herbert got an early start in grant writing during graduate school at the University of Texas, Austin, when a visiting lecturer from NASA encouraged her to apply for a fellowship, and she won it. Herbert says that applying for that first grant forced her to organize her thinking about the next steps in her research. As a postdoc in the lab run by telomerase re-searchers Jerry Shay and Woody Wright at the UT Southwestern Medical Center, Dallas, Herbert put her graduate

Photo: Courtesy of Karen Vousden Karen H. Vousden, head of the Cell Growth Regulation Laboratory at the National Cancer Institute, Frederick, Md., and her friend Xin Lu, a professor at the Ludwig Institute for Cancer Research in London, found a way to get instant recognition at the many p53 meetings they attend: They wear similar blue sweaters. Twins from separate nations, the chums may have started a trend. At the 11th International p53 Workshop in Barcelona this past May, the pals teased two